Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Reuters continues to rate PTSC "Outperform"; comparisons interesting

Reuters continues to rate PTSC "Outperform"; comparisons interesting

posted on Sep 18, 2007 10:44AM

Reuters continues to stick by it's rating of PTSC, giving them it's highest rating of "OUTPERFORM".  I don't know how often they review their ratings but it has been lower in the past.

If you have access (Waterhouse clients have access) to this report it's worth the read.

What I find interesting is the "Peer Comparisons" comprised of PTSC, MIPS and TMTAD. The only area that PTSC comes out worse than Peers is in technical factors, which is primarily an issue of "share price movement".

Although PTSC comes out ahead in 4 of 5 catagories (5th = share price movement), and overall gets Reuters' top rating (outperform), they remain way behind when it comes to P/E ratio. Go figure.

PTSC P/E = 9

MIPS P/E = 39

TMTAD P/E = couldn't find this one


Sep 18, 2007 10:57AM
Share
New Message
Please login to post a reply